NCT05595889

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

Efficacy and Safety of Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer: a Single-arm, Prospective, Exploratory Clinical Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the clinical efficacy and safety of surufatinib combined with irinotecan in the second line treatment of small cell lung cancer.

Detailed description

According to the inclusion and exclusion criteria, 40 patients with small cell lung cancer who failed to receive standard first-line therapy were selected to evaluate the efficacy and safety of surufatinib combined with irinotecan in the second-line treatment of small cell lung cancer.

Conditions

• Small Cell Lung Cancer
• Angiogenesis
• Chemotherapy Effect

Interventions

Type	Name	Description
DRUG	Surufatinib	250 mg/day p.o. QD
DRUG	Irinotecan	Participants will receive irinotecan，100 mg/m2，Intravenous drip, day 1 and day 8 of every 3 weeks

Timeline

• Start date: 2022-12-01
• Primary completion: 2024-09-30
• Completion: 2025-09-30
• First posted: 2022-10-27
• Last updated: 2022-11-29